- Home
- OCGN vs VYGR Comparison
OCGN vs VYGR Comparison
Compare OCGN & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- VYGR
- Stock Information
- Founded
- OCGN 2013
- VYGR 2013
- Country
- OCGN United States
- VYGR United States
- Employees
- OCGN N/A
- VYGR N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- OCGN Health Care
- VYGR Health Care
- Exchange
- OCGN Nasdaq
- VYGR Nasdaq
- Market Cap
- OCGN 338.2M
- VYGR 386.1M
- IPO Year
- OCGN N/A
- VYGR 2015
- Fundamental
- Price
- OCGN $0.99
- VYGR $7.13
- Analyst Decision
- OCGN Strong Buy
- VYGR Strong Buy
- Analyst Count
- OCGN 3
- VYGR 7
- Target Price
- OCGN $5.33
- VYGR $17.43
- AVG Volume (30 Days)
- OCGN 3.5M
- VYGR 673.5K
- Earning Date
- OCGN 11-08-2024
- VYGR 11-12-2024
- Dividend Yield
- OCGN N/A
- VYGR N/A
- EPS Growth
- OCGN N/A
- VYGR N/A
- EPS
- OCGN N/A
- VYGR 0.18
- Revenue
- OCGN $7,263,000.00
- VYGR $143,769,000.00
- Revenue This Year
- OCGN N/A
- VYGR N/A
- Revenue Next Year
- OCGN N/A
- VYGR N/A
- P/E Ratio
- OCGN N/A
- VYGR $40.04
- Revenue Growth
- OCGN 112.62
- VYGR N/A
- 52 Week Low
- OCGN $0.35
- VYGR $5.71
- 52 Week High
- OCGN $2.11
- VYGR $11.72
- Technical
- Relative Strength Index (RSI)
- OCGN 50.03
- VYGR 53.58
- Support Level
- OCGN $0.91
- VYGR $6.40
- Resistance Level
- OCGN $0.98
- VYGR $7.39
- Average True Range (ATR)
- OCGN 0.07
- VYGR 0.43
- MACD
- OCGN 0.02
- VYGR -0.00
- Stochastic Oscillator
- OCGN 40.08
- VYGR 79.84
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.